Form 4: CFO Sells BeOne Medicines ADSs for Tax Withholding

BeOne Medicines' CFO, Aaron Rosenberg, sold 1,190 American Depositary Shares at $290.47 each to cover mandatory tax withholding related to a restricted share unit award.

Summary

• Aaron Rosenberg, Chief Financial Officer of BeOne Medicines Ltd., sold 1,190 American Depositary Shares (ADSs) on August 1, 2025.
• The sale was executed at a price of $290.47 per ADS.
• This transaction was for mandatory tax withholding in connection with the vesting of a previously granted restricted share unit (RSU) award.
• Each American Depositary Share represents 13 Ordinary Shares.
• The underlying RSU award vests 1/4th on each anniversary of July 31, 2024, contingent on continued service.
• Unvested securities are subject to accelerated vesting under certain termination events.

Sentiment

Score: 6

Explanation: The transaction is a routine, non-discretionary sale for tax withholding purposes, which is a neutral event. The vesting of RSUs is generally positive as it indicates executive compensation and retention, but the sale itself is merely administrative.

Positives

• The sale is a routine transaction for tax purposes, indicating the vesting of previously granted equity awards to a key executive.
• The vesting schedule provides an incentive for continued service from the Chief Financial Officer.

Negatives

• The sale reduces the direct beneficial ownership of American Depositary Shares by a key executive, although it's for tax purposes rather than a discretionary sale.

Future Outlook

The restricted share unit award vests 1/4th on each anniversary of July 31, 2024, subject to continued service, with provisions for accelerated vesting upon certain termination events.

Management Comments

• The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement.

Industry Context

This is a routine insider transaction related to executive compensation, common across all industries for publicly traded companies. It does not reflect broader industry trends.

Stakeholder Impact

• Shareholders: Minimal direct impact as it's a routine tax-related sale, not a discretionary divestment. It reflects the ongoing compensation structure for executives.
• Management: The vesting and subsequent tax sale are part of the CFO's compensation package, indicating continued equity incentives.

Next Steps

• Future vesting of 1/4th of the restricted share units on each anniversary of July 31, 2024.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by the CFO for tax withholding purposes upon the vesting of restricted share units. Such transactions are common and do not typically signal a change in the company's fundamentals or management's outlook. Therefore, it provides no new information that would warrant a change in investment recommendation.

Keywords

BeOne Medicines, ONC, SEC Form 4, Insider Trading, CFO, Aaron Rosenberg, Restricted Share Units, Tax Withholding, Equity Compensation, American Depositary Shares